Stevia and Blood Pressure

This is the weakest of stevia's four commonly cited benefits, and this page says so at the top rather than at the bottom. The blood-pressure claim rests on a small number of long trials conducted by a small number of related research groups, using stevioside at doses many times higher than anyone consumes as a sweetener, and it was not reproduced when independent groups elsewhere tried. Later trials designed to detect a blood-pressure effect found none.

That does not make the original results fraudulent or uninteresting. It makes them unreplicated, which in clinical research is a specific and important status. This page lays out what was found, by whom, at what dose, and what happened when others looked.

Where the Claim Comes From
The Proposed Mechanism
The Positive Trials
The Trials That Found Nothing
The Dose Gap
Reading an Unreplicated Literature
What the Systematic Reviews Concluded
The Indirect Route That Does Work
Which "Stevia" Was Even Tested
What Actually Lowers Blood Pressure
Key Research Papers
Safety Note and Disclaimer
Connections

1. Where the Claim Comes From

Between 2000 and 2003, two clinical trials from research groups in Taiwan and China reported that oral stevioside lowered blood pressure substantially in people with hypertension, over trial durations of one and two years respectively. Those two papers are the origin of essentially every "stevia lowers blood pressure" claim in circulation today, twenty-odd years later.

Long randomized trials in hypertension are rare and expensive, so a one-year and a two-year trial carry real weight on paper. The problem is what happened next, or rather what did not.

2. The Proposed Mechanism (Evidence Tier: Preliminary — Animal and In Vitro)

The mechanistic story is coherent, which is part of why the claim persists. Work in isolated vessels and in animals has reported that stevioside and its aglycone steviol reduce calcium influx through voltage-gated calcium channels in vascular smooth muscle, producing vasodilation. That is broadly the mechanism of the dihydropyridine calcium channel blocker drug class — amlodipine and its relatives.

Additional preclinical reports have proposed effects on nitric-oxide-mediated vasorelaxation, on renin-angiotensin signalling, and on renal handling of sodium. Some spontaneously hypertensive rat studies show blood-pressure reduction with stevioside.

Every one of those findings is preclinical. A compound that relaxes an isolated aortic ring at a bath concentration says nothing about whether the same compound reaches a comparable concentration at the same tissue in a living person consuming milligrams of it in coffee. In stevia's case there is a specific reason to doubt that it does: steviol glycosides are not absorbed intact, and what reaches the circulation is steviol glucuronide, a conjugate on its way to the kidney — not the parent glycoside used in the vessel-bath experiments.

PubMed: stevioside, vasorelaxation and calcium channels

3. The Positive Trials (Evidence Tier: Clinical, Not Replicated)

Chan and colleagues (2000), A double-blind placebo-controlled study of the effectiveness and tolerability of oral stevioside in human hypertension, British Journal of Clinical Pharmacology. Adults with hypertension received 250 mg of stevioside three times daily — 750 mg/day — for one year. The stevioside group showed significant reductions in systolic and diastolic blood pressure compared with placebo, with the effect appearing within about a week and sustained over the year. Tolerability was reported as good.
Hsieh and colleagues (2003), Efficacy and tolerability of oral stevioside in patients with mild essential hypertension: a two-year, randomized, placebo-controlled study, Clinical Therapeutics. A larger and longer trial — 500 mg of stevioside three times daily, 1,500 mg/day, for two years — in people with mild essential hypertension. It again reported significant falls in systolic and diastolic blood pressure versus placebo, along with reported improvements in quality-of-life measures and no significant adverse effects.

Both are properly randomized, placebo-controlled and double-blind. Neither is a small pilot. On their own terms they are decent trials.

PubMed: stevioside and hypertension, randomized trials

4. The Trials That Found Nothing (Evidence Tier: Clinical)

Independent groups elsewhere tried and did not reproduce the finding.

Ferri and colleagues (2006), Investigation of the antihypertensive effect of oral crude stevioside in patients with mild essential hypertension, Phytotherapy Research. Conducted in Brazil, in the same patient population the earlier trials targeted, with an escalating stevioside dose. No significant antihypertensive effect was found.
Barriocanal and colleagues (2008), Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans, Regulatory Toxicology and Pharmacology. Three months of 750 mg/day of steviosides — the same daily dose as Chan 2000 — in people with type 1 diabetes, type 2 diabetes and healthy normotensive controls. Blood pressure was a pre-specified measurement. No effect was found. The paper's title states its conclusion.
Maki and colleagues (2008), The hemodynamic effects of rebaudioside A in healthy adults with normal and low-normal blood pressure, Food and Chemical Toxicology. A trial designed specifically around the hypotension question, giving 1,000 mg/day of rebaudioside A. No clinically meaningful change in blood pressure or heart rate. The companion trial in adults with type 2 diabetes, published in the same journal and year, found the same.

Note the shape of this. The negative trials were not underpowered afterthoughts — two of them were designed with blood pressure as a specified endpoint, at doses equal to or above those used in the positive trials.

5. The Dose Gap — Why This Is Not About Sweetener Use At All

Even taking the positive trials entirely at face value, they do not describe sweetener consumption. They describe drug administration.

Chan 2000 used 750 mg/day of stevioside. Hsieh 2003 used 1,500 mg/day.
The JECFA Acceptable Daily Intake is 4 mg/kg body weight/day as steviol equivalents. For a 70 kg adult that is 280 mg/day of steviol equivalents, which for stevioside (conversion factor about 0.40) corresponds to roughly 700 mg of stevioside.
So the Hsieh dose sits at roughly twice the ADI, taken daily for two years. The Chan dose sits at approximately the ADI.
Actual tabletop consumption is nowhere near either. A packet contains a few milligrams of glycoside. Intake surveys in Europe and North America generally find even high consumers well below the ADI.

The practical translation is blunt: if the blood-pressure effect were real, you would not obtain it by sweetening your coffee. You would obtain it by taking purified stevioside capsules three times a day at a dose at or above the internationally agreed intake limit, indefinitely. That is not a sweetener strategy; it is unsupervised self-medication with an unapproved drug.

6. How to Read a Literature That Did Not Replicate

Two features of this evidence base deserve stating plainly, because they are the reason systematic reviewers have been unenthusiastic:

Geographic and group clustering. The positive results came from a small number of related investigators working in one region. The negative results came from independent groups in Brazil and the United States. When a finding survives only within its originating group, the most common explanations are population differences, methodological differences, or publication and analytical choices — not necessarily any of them, but the clustering itself is the signal.
Failure to replicate is more informative than the original positive. This is uncomfortable but standard. A positive result establishes a hypothesis; a well-powered negative replication at the same or higher dose substantially weakens it. Here there are three such replications.

There are legitimate counter-arguments. Trial durations differed — one and two years versus three to four months — and it is conceivable that a slow vascular effect needs longer than a season to appear. Baseline blood pressure differed between populations, and antihypertensive effects are generally larger in people with higher starting pressure. Crude stevioside preparations differ from purified rebaudioside A in composition. None of these rescue the claim; they only explain why it has not been definitively closed.

7. What the Systematic Reviews Concluded

Onakpoya and Heneghan (2015), Effect of the natural sweetener, steviol glycoside, on cardiovascular risk factors: a systematic review and meta-analysis of randomised clinical trials, European Journal of Preventive Cardiology, pooled the available randomized evidence on steviol glycosides and cardiovascular risk factors including blood pressure. The review found the evidence insufficient to establish a clinically meaningful effect, and highlighted the small number of trials, the heterogeneity between them and the risk of bias.

Toews and colleagues (2019), Association between intake of non-sugar sweeteners and health outcomes: systematic review and meta-analyses of randomised and non-randomised controlled trials and observational studies, BMJ, examined non-sugar sweeteners across a wide range of endpoints including blood pressure and found no convincing evidence of health benefit at the doses studied.

The consistent conclusion of the review literature is that steviol glycosides should not be recommended for blood-pressure management.

PubMed: steviol glycosides and cardiovascular risk factors, systematic review

8. The Indirect Route That Does Work

There is a real, evidence-backed way stevia can end up associated with better blood pressure, and it has nothing to do with vascular smooth muscle.

High intake of sugar-sweetened beverages is associated with higher blood pressure and with weight gain, and weight loss is one of the most reliable non-drug blood-pressure interventions there is — roughly 1 mmHg of systolic reduction per kilogram lost, in the trial literature. Replacing sugary drinks with stevia-sweetened ones reduces calorie intake modestly, as covered on the Weight and Calorie Control page. McGlynn and colleagues (2022) in JAMA Network Open found that substituting low- and no-calorie sweetened beverages for sugar-sweetened ones improved body weight and several cardiometabolic markers.

That is a genuine benefit obtained by an entirely ordinary mechanism: less sugar, less weight, lower pressure. It is worth having. It is also not what the supplement copy is claiming.

9. Which "Stevia" Was Even Tested

The three products sold under the name behave differently here as everywhere else:

Whole stevia leaf — traditional Guaraní use, not approved as a sweetener in the US or EU. No blood-pressure trial has used whole leaf. The traditional record does not include an antihypertensive indication either.
Purified steviol glycosides (E 960) — what the trials used, in capsule form at pharmacological doses. Chan and Hsieh used crude or purified stevioside; Maki used rebaudioside A. These are different compounds sharing one core, and it is at least possible they behave differently, though nothing establishes that they do.
Retail tabletop products — mostly erythritol or dextrose with a trace of rebaudioside. Nothing in any trial says anything about these. The Microbiome and Safety page covers the separate 2023 cardiovascular signal attached to erythritol, which is a bulking-agent question and not a stevia question — a distinction almost universally lost in news coverage.

10. What Actually Lowers Blood Pressure

If blood pressure is the goal, these have the evidence stevia lacks:

Sodium reduction — the DASH-Sodium trials remain among the clearest dietary evidence in cardiology.
Weight loss — approximately 1 mmHg systolic per kilogram in trial data.
Aerobic exercise — see Exercise.
Dietary potassium from vegetables and fruit.
Alcohol reduction.
The DASH and Mediterranean dietary patterns — see Mediterranean Diet.
Prescribed antihypertensive medication where indicated. See Hypertension.

11. Key Research Papers

Cited as PubMed search links rather than record numbers; resolve each from the stated title, journal and year.

Chan P et al. A double-blind placebo-controlled study of the effectiveness and tolerability of oral stevioside in human hypertension. British Journal of Clinical Pharmacology, 2000. — Find on PubMed
Hsieh MH et al. Efficacy and tolerability of oral stevioside in patients with mild essential hypertension: a two-year, randomized, placebo-controlled study. Clinical Therapeutics, 2003. — Find on PubMed
Ferri LA et al. Investigation of the antihypertensive effect of oral crude stevioside in patients with mild essential hypertension. Phytotherapy Research, 2006. — Find on PubMed
Barriocanal LA et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. Regulatory Toxicology and Pharmacology, 2008. — Find on PubMed
Maki KC et al. The hemodynamic effects of rebaudioside A in healthy adults with normal and low-normal blood pressure. Food and Chemical Toxicology, 2008. — Find on PubMed
Maki KC et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology, 2008. — Find on PubMed
Onakpoya IJ, Heneghan CJ. Effect of the natural sweetener, steviol glycoside, on cardiovascular risk factors: a systematic review and meta-analysis of randomised clinical trials. European Journal of Preventive Cardiology, 2015. — Find on PubMed
Toews I et al. Association between intake of non-sugar sweeteners and health outcomes: systematic review and meta-analyses of randomised and non-randomised controlled trials and observational studies. BMJ, 2019. — Find on PubMed
McGlynn ND et al. Association of low- and no-calorie sweetened beverages as a replacement for sugar-sweetened beverages with body weight and cardiometabolic risk. JAMA Network Open, 2022. — Find on PubMed
Geuns JM. Stevioside. Phytochemistry, 2003. — Find on PubMed
Ashwell M. Stevia, nature's zero-calorie sustainable sweetener: a new player in the fight against obesity. Nutrition Today, 2015. — Find on PubMed
Samuel P et al. Stevia leaf to stevia sweetener: exploring its science, benefits, and future potential. The Journal of Nutrition, 2018. — Find on PubMed

12. Safety Note and Disclaimer

Do not use stevia to treat high blood pressure, and do not reduce or stop antihypertensive medication because you have started using it. Untreated hypertension causes stroke, heart failure, kidney disease and vision loss, usually without symptoms until damage is done.

Purified steviol glycosides are considered safe within the ADI by JECFA, the FDA and EFSA at sweetener-level intakes. The capsule doses used in the trials above are a different matter: taking 750 to 1,500 mg of stevioside daily for years is unsupervised use of a compound at or above its intake limit, and no regulator has evaluated that pattern of use for chronic safety. If you take antihypertensive medication and choose to consume stevia at high doses anyway, the theoretical concern is additive hypotension — discuss it with your prescriber and monitor your pressure.

Nothing on this page is medical advice, a diagnosis, or a recommendation to alter prescribed treatment. This site is an educational resource, not a treatment service.

Connections

Back to Table of Contents